Detailed Information
Cited 0 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
4-year survival in randomised phase II (POPLAR) and phase III (OAK) studies of atezolizumab (atezo) vs docetaxel (doc) in pre-treated NSCLC
- Authors
- Mazieres, J[Mazieres, J.]; Rittmeyer, A[Rittmeyer, A.]; Gadgeel, SM[Gadgeel, S. M.]; Hida, T[Hida, T.]; Gandara, D[Gandara, D.]; Cortinovis, D[Cortinovis, D.]; Barlesi, F[Barlesi, F.]; Yu, W[Yu, W.]; Matheny, C[Matheny, C.]; Ballinger, M[Ballinger, M.]; Park, K[Park, K.]
- Issue Date
- Sep-2020
- Publisher
- ELSEVIER
- Citation
- ANNALS OF ONCOLOGY, v.31, pp.S821 - S822
- Indexed
- SCIE
SCOPUS
- Journal Title
- ANNALS OF ONCOLOGY
- Volume
- 31
- Start Page
- S821
- End Page
- S822
- ISSN
- 0923-7534
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.